Context Therapeutics/$CNTX
1D1W1MYTD1Y5YMAX
Capital at risk
About Context Therapeutics
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
- Ticker
- $CNTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 15
- Headquarters
- Philadelphia, United States
- Website
- www.contexttherapeutics.com
CNTX Metrics
BasicAdvanced
$34M
-
-$0.48
1.74
-
Price and volume
Market cap
$34M
Beta
1.74
52-week high
$3.62
52-week low
$0.34
Average daily volume
1.9M
Financial strength
Current ratio
5.811
Quick ratio
5.452
Long term debt to equity
0.002
Total debt to equity
0.006
Profitability
EBITDA (TTM)
-48.707
Management effectiveness
Return on assets (TTM)
-45.70%
Return on equity (TTM)
-76.14%
Valuation
Price to book
0.89
Price to tangible book (TTM)
0.89
Price to free cash flow (TTM)
-0.865
Free cash flow yield (TTM)
-115.67%
Free cash flow per share (TTM)
-0.426
Growth
Earnings per share change (TTM)
24.60%
3-year earnings per share growth (CAGR)
-25.62%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.